W
Winnie Yeo
Researcher at The Chinese University of Hong Kong
Publications - 291
Citations - 19511
Winnie Yeo is an academic researcher from The Chinese University of Hong Kong. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 60, co-authored 282 publications receiving 16440 citations. Previous affiliations of Winnie Yeo include University of Hong Kong.
Papers
More filters
Journal ArticleDOI
Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer: Study protocol clinical trial (SPIRIT Compliant).
Carmen W.H. Chan,Christine Miaskowski,Alexandra L. McCarthy,Mary M.Y. Waye,Winnie Yeo,Winnie Kwok Wai So,Kai Chow Choi,Stephen Kwok-Wing Tsui,Judy Yuet-Wa Chan +8 more
TL;DR: This research presents a novel probabilistic procedure called “spot-spot analysis” that allows for real-time analysis of the response of the immune system to foreign substance abuse.
Journal ArticleDOI
Weight and waist-to-hip ratio change pattern during the first five years of survival: data from a longitudinal observational Chinese breast cancer cohort.
Yuan-Yuan Lei,Suzanne C. Ho,Carol Kwok,Ashley Cheng,Ka Li Cheung,Roselle Lee,Frankie Mo,Winnie Yeo +7 more
TL;DR: Weight gain was modest in Chinese breast cancer survivors during the first five years of survival, while central adiposity has become a contemporary public health issue.
Short communication Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling
Zachariah E. Selvanayagam,T. H. Cheung,Nien Wei,Ragini Vittal,Keith W.K. Lo,Winnie Yeo,Tsunekazu Kita,Roald Ravatn,Tony Kwok,Hung Chung,Yick Fu Wong,Khew-Voon Chin +11 more
TL;DR: A cDNA microarray examination of the expression profiles of eight primary ovarian cancers stratified into two groups based on their chemotherapeutic response was conducted and gene expression profiling by means of DNA microarray may be applied diagnostically for predicting treatment response in ovarian cancer.
Journal ArticleDOI
Bone Health in Premenopausal Chinese Patients after Adjuvant Chemotherapy for Early Breast Cancer.
Claudia H. W. Yip,Giok S. Liem,Frankie Mo,Elizabeth Pang,Yuan-Yuan Lei,Leung Li,Christopher C. H. Yip,Jane Koh,Rita Y. W. Ng,Joyce J. S. Suen,Winnie Yeo +10 more
TL;DR: About 5 years after breast cancer diagnosis and adjUvant chemotherapy, >50% of premenopausal patients who had received adjuvant chemotherapy were detected to have osteopenia/osteoporosis and 40% had abnormal Z-scores for FN/LS.
Journal ArticleDOI
Abstract P3-03-03: Risk factors associated with chemotherapy-induced nausea and vomiting among breast cancer patients receiving highly emetogenic chemotherapy
TL;DR: Yeo et al. as mentioned in this paper identified the risk factors related to chemotherapy-induced nausea and vomiting (CINV) development in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide chemotherapy.